Brief: Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease
29/12/2021 12:36
Dec 29 (Reuters) - Statera Biopharma Inc STAB.O :
* STATERA BIOPHARMA SUBMITS PHASE 3 CLINICAL TRIAL PROTOCOL
TO FDA
FOR INVESTIGATIONAL TREATMENT OF PEDIATRIC CROHN’S DISEASE
* STATERA BIOPHARMA INC - TRIAL SITES ARE CURRENTLY BEING
SELECTED
AND ENROLLMENT IS EXPECTED TO LAUNCH IN EARLY 2022
Source text for Eikon: ID:nGNX60Ck2L
Further company coverage: STAB.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Statera Biopharma
See all news20/20 Biolabs jumps on Ebola, hantavirus testing plans
Tivic Health Systems rises after deal for late-stage immunotherapy drug
Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
Brief: Statera Biopharma Inc Quarterly Loss Per Share $0.20
Brief: Statera Biopharma Inc - On October 12, 2022, Co Entered A Binding Memorandum Of Understanding (“MoU”) With Holobeam Technologies, Inc